Kura Oncology's Ziftomenib Receives FDA Priority Review for NPM1-Mutant AML, PDUFA Date Set for November 2025
核心洞察
Kura Oncology's lead asset ziftomenib has advanced to FDA Priority Review for relapsed/refractory NPM1 (搜索)-mutant acute myeloid leukemia (搜索), with a PDUFA date of November 30, 2025.
The KOMET-001 pivotal trial demonstrated a 23% complete remission rate in heavily pretreated, high-risk patients, with manageable safety profile and no significant cardiac safety issues.
Ziftomenib is the only menin (搜索) inhibitor to receive both Priority Review and Breakthrough Therapy Designation for this indication, positioning it as a potential first-in-class treatment.
Kura Oncology has achieved a significant regulatory milestone with its lead menin (搜索) inhibitor ziftomenib receiving FDA Priority Review for the treatment of relapsed/refractory NPM1 (搜索)-mutant acute myeloid leukemia (搜索) (AML). The company announced that the Prescription Drug User Fee Act (PDUFA) date has been set for November 30, 2025, marking a critical juncture for the clinical-stage oncology company.
Breakthrough Regulatory Status
Ziftomenib stands out as the only menin (搜索) inhibitor to receive both Priority Review and Breakthrough Therapy Designation for NPM1-mutant AML (搜索), a genetically defined subtype of leukemia with limited current treatment options. This dual designation underscores the FDA's recognition of the drug's potential to address an unmet medical need in a heavily pretreated, high-risk patient population.
The regulatory advancement follows the submission of a New Drug Application (NDA) based on data from the KOMET-001 pivotal trial. The study demonstrated a 23% rate of complete remission (CR) and CR with partial hematologic recovery (CRh) in patients with relapsed or refractory NPM1-mutant AML (搜索), as presented at the 2025 ASCO Annual Meeting.
Clinical Safety Profile
Safety data from the KOMET-001 trial showed a manageable profile for ziftomenib, with low rates of myelosuppression and treatment discontinuation. Notably, the trial revealed no significant cardiac safety issues, addressing a key concern in cancer therapeutics. These safety findings are particularly important given the heavily pretreated nature of the patient population enrolled in the study.
Financial Performance and Strategic Partnerships
Kura Oncology reported Q2 2025 collaboration revenue of $15.3 million, falling short of analyst expectations of $39.1 million. All revenue continues to come from partnership agreements, primarily with Kyowa Kirin, as the company has no current product sales. Research and development expenses increased 58% to $62.8 million compared to Q2 2024, reflecting the expansion of clinical programs and progression of late-stage trials.
The company's net loss widened to $66.1 million in Q2 2025, up 30% from the $50.8 million loss in the same period last year. General and administrative expenses also rose 51% to $25.2 million, driven by pre-launch hiring, commercial infrastructure development, and scaling of corporate functions in preparation for potential ziftomenib approval.
Cash Position and Future Operations
Despite increased spending, Kura Oncology maintains a strong financial position with $630.7 million in cash, cash equivalents, and short-term investments as of June 30, 2025. Management asserts this funding is sufficient to support current operations into 2027, with additional collaboration funding from Kyowa Kirin expected upon achievement of clinical and regulatory milestones.
Expanding Pipeline and Clinical Development
Beyond ziftomenib, Kura Oncology is diversifying its research portfolio with a next-generation menin (搜索) inhibitor for diabetes (搜索) and cardiometabolic diseases. The company is also advancing KO-2806, a farnesyl transferase (搜索) inhibitor, in solid tumors including renal cell carcinoma (搜索) through the FIT-001 and KOMET-007 trials, with data readouts expected later in 2025.
The company plans to initiate two pivotal Phase 3 registrational trials in the second half of 2025, further expanding its clinical development program. Additionally, Kura Oncology has three clinical abstracts accepted for presentation at the 2025 ESMO Congress, demonstrating continued scientific engagement and data generation across its pipeline.
Market Position and Competition
As the only menin (搜索) inhibitor with both Priority Review and Breakthrough Therapy Designation for NPM1-mutant AML (搜索), ziftomenib holds a potentially advantageous position in a competitive landscape. However, the company acknowledges that competition in menin inhibitors remains strong, making the upcoming FDA decision and ongoing clinical trial results critical for future strategy and resource allocation.